Overview

Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)

Status:
Completed

Trial end date:
2018-02-08

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin alone or on insulin in combination with metformin stably for 8 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

LG Life Sciences

Treatments:

Insulin
Metformin